Hannah P Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/247922/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Burden of Gastrointestinal Disease in the United States: 2012 Update. Gastroenterology, 2012, 143, 1179-1187.e3.	1.3	1,725
2	A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointestinal Endoscopy, 2014, 79, 577-585.e4.	1.0	384
3	The Prevalence and Diagnostic Utility of Endoscopic Features of Eosinophilic Esophagitis: A Meta-analysis. Clinical Gastroenterology and Hepatology, 2012, 10, 988-996.e5.	4.4	283
4	Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021. Gastroenterology, 2022, 162, 621-644.	1.3	254
5	Focal endoscopic mucosal resection before radiofrequency ablation is equally effective and safe compared with radiofrequency ablation alone for the eradication of Barrett's esophagus with advanced neoplasia. Gastrointestinal Endoscopy, 2012, 76, 733-739.	1.0	67
6	Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis. Clinical Gastroenterology and Hepatology, 2018, 16, 1992-1994.	4.4	37
7	What Survivorship Means to Liver Transplant Recipients: Qualitative Groundwork for a Survivorship Conceptual Model. Liver Transplantation, 2021, 27, 1454-1467.	2.4	12
8	What Liver Transplant Recipients Want in a Smartphone Intervention to Enhance Recovery: Prototype for the LiveRight Transplant App. Liver Transplantation, 2021, 27, 584-589.	2.4	11
9	Early Survivorship After Liver Transplantation: A Qualitative Study Identifying Challenges in Recovery From the Patient and Caregiver Perspective. Liver Transplantation, 2022, 28, 422-436.	2.4	11
10	Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Alimentary Pharmacology and Therapeutics, 2021, 54, 1472-1480.	3.7	10
11	The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 2199-2201.	4.4	8
12	A Systematic Review of Patientâ€Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Hepatology Communications, 2020, 4, 1502-1515.	4.3	8
13	"lf I Get Cured, My Whole Quality of Life Will Change― Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C. Digestive Diseases and Sciences, 2022, 67, 100-120.	2.3	7
14	Successful liver transplantation in patients with active SARS-CoV-2 infection. American Journal of Transplantation, 2022, 22, 2694-2696.	4.7	7
15	Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107706.	2.3	3
16	Symptoms and functioning improve after chronic hepatitis C cure as assessed by the Memorial Symptom Assessment Scale and PROMIS measures. Journal of Viral Hepatitis, 2021, 28, 1491-1495.	2.0	3
17	Editorial: targeting liver biopsy in NAFLD—the need to expand our nonâ€invasive tools. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 128-128.	3.7	0